PTC Therapeutics (PTCT) Tops Q2 EPS by 6c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.06 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $7.74 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance